Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Orange, California
Dates
study started
estimated completion
Principal Investigator
by Farshid Dayyani

Description

Summary

This is a phase 2, prospective, two-arm, randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.

Official Title

Proof of Concept Study of ctDNA Guided Change in Treatment for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Details

Treatment on study will be administered in 14 day cycles.

Keywords

Colon Adenocarcinoma Colorectal Cancer Adenocarcinoma Neoplasm, Residual Irinotecan TAS-102 Signatera MRD ctDNA Assay TASIRI

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Patients must have histologically or cytologically confirmed adenocarcinoma of the colon (high rectal cancer is eligible if resected and no radiation needed). Other histologies which are treated per NCCN guidelines for adjuvant colon cancer are eligible.
  2. Must have Stage II or Stage III colorectal cancer eligible for adjuvant doublet chemotherapy for 6 months.
  3. Must have ctDNA positive assay (tested by Signatera MRD assay) after 3 months of adjuvant chemotherapy
  4. Age ≥ 18 years
  5. Performance status: ECOG performance status ≤2
  6. Life expectancy of greater than 3 months
  7. Adequate organ and marrow function as defined below:
  8. leukocytesL ≥ 3,000/mcL
  9. absolute neutrophil count: ≥ 1,500/mcL
  10. platelets: ≥ 80,000/mcl
  11. total bilirubin: within normal institutional limits
  12. AST(SGOT)/ALT(SPGT): ≤ 3 X institutional upper limit of normal or ≤ 5 X if liver metastases are present
  13. creatinine: <1.5 X ULN
  14. The effects of TAS-102 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because topoisomerase inhibitors are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  15. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
  16. Has not undergone a hysterectomy or bilateral oophorectomy; or
  17. Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
  18. Ability to swallow tablets
  19. . Ability to understand and the willingness to sign a written informed consent.

You CAN'T join if...

  1. Patients who have had major surgery within 4 weeks, or chemotherapy or radiotherapy within 2 weeks prior to Cycle 1 Day 1
  2. All toxicities attributed to prior anti-cancer therapy other than alopecia must have resolved to grade 1 or baseline
  3. Patients may not be receiving any other investigational agents.
  4. Patients with known metastases.
  5. History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS-102, irinotecan or other agents used in study.
  6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  7. Prior treatment with irinotecan or TAS-102.
  8. History of another primary cancer within the last 3 years with the exception of non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ.
  9. Inability to comply with study and follow-up procedures as judged by the Investigator
  10. . Patients who are pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants. -

Location

  • Chao Family Comprehensive Cancer Center, University of California, Irvine
    Orange California 92868 United States

Lead Scientist at UC Irvine

  • Farshid Dayyani
    Clinical Professor, Medicine. Authored (or co-authored) 52 research publications.

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Irvine
ID
NCT04920032
Phase
Phase 2
Study Type
Interventional
Last Updated